Loading...
The safety and efficacy of structured treatment interruption (STI) were called into question last year when the SMART study (ACC Nov 29 2006) and the Trivacan ANRS 1269 study (Lancet 2006; 367:1981) both demonstrated higher rates of clinical events (mostly non–AIDS-defining) with STI than with continued antiretroviral therapy. Both studies used a CD4 count <250 cells/mm3 as the threshold for treatment resumption. In the present study, called TIBET, investigators evaluated the safety of STI versus continued therapy in 201 HIV-infected patients with baseline CD4 counts >500 cells/mm3 and baseline viral loads <50 copies/mL. Patients randomized to STI resumed therapy when their CD4 counts fell below 350 cells/mm3 or their viral loads exceeded 1…